Support Group Leader Blogs

Post-ASH Reflections

Post-ASH Reflections

The ASH21 Meeting of blood diseases is in the books. What I can share with patients, care partners, and all who are interested is that the myeloma research world is on fire! There are so many new questions for new and veteran researchers, so many creative possible...

‘Extra’ is Not Always Better

‘Extra’ is Not Always Better

The diagnosis of multiple myeloma is just that — “multiple.” There are so many manifestations of this one diagnosis that you could have 10 people with multiple myeloma in a room and you could hear 10 different versions of their diagnosis and treatment.  ...

Power Over Your Mind

Power Over Your Mind

“You have power over your mind – not outside events.  Realize this, and you will find your strength.”—Marcus Aurelius, Meditations As the 63rd annual meeting of the American Society of Hematology (ASH) wrapped up this week, I am looking to the future with...

End of the Line: The IMF’s Best of ASH!

End of the Line: The IMF’s Best of ASH!

Before ASH even started, there were many educational Satellite Symposiums taking place.  The IMF’s program is CME-certified and available online (Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple...

Post-ASH: Words Matter

Post-ASH: Words Matter

As I’m writing my last blog for ASH 2021, I am inspired to write about the topics that stoked my fire. You know, the ones that were a gut check, the ones that I couldn’t stop thinking about, the ones that I felt deep down in my soul —topics that I feel are ones to...

That’s an ASH Wrap!

That’s an ASH Wrap!

Attending the 63rd American Society of Hematology (ASH) meeting for the first time was an illuminating experience! I feel quite privileged to be a part of the International Myeloma Foundation (IMF) team and to have this educational opportunity. This was an amazing...

Post-ASH: Seeing in the Sand

Post-ASH: Seeing in the Sand

“Any fool can turn a blind eye but who knows what the ostrich sees in the sand.” - Samuel Barclay Beckett Colon cancer screening has been shown to reduce the incidence of colon cancer in the general population by identifying premalignant lesions in the colon and...

Algorithms:  Which Treatment and When?

Algorithms: Which Treatment and When?

I am so thankful and impressed with the content and variety of topics that the #IMFASH21 support group leaders are reporting through their blogs. Each brings important highlights that will be helpful in Support Group discussions.   For those who do not...

Mental Health and Myeloma Research

Mental Health and Myeloma Research

As I mentioned in my previous blog, “What are You Going to Fill Your Glass with?” I reviewed a variety of sessions dealing with various aspects of mental health. Almost all of them were poster sessions, which I personally like because they have such a different feel...

ASH 2021 May Be Over, But This is Not the End

ASH 2021 May Be Over, But This is Not the End

On Monday, the 63rd Annual Meeting and Exposition of the American Society of Hematology came to an end. The hybrid model worked for the most part. Like any live event, there were technology hiccups here and there.  Here are my five takeaways from the meeting. ...

ASH Day 3: It’s a Wrap!

ASH Day 3: It’s a Wrap!

December 13, 2021 - Today was the final day of ASH but it was still full of information, and to be honest, I’m a bit brain-fried.  The day began with the IMWG Conference series (with the replay available on the IMF website). I jotted a few quotes that I...

Off the Beaten Path

Off the Beaten Path

There are so many amazing programs available to attend at the American Society of Hematology (#ASH21) meeting.  Scientific and Clinical Education spotlights, award ceremonies, poster and oral abstracts covering everything from “bench to bedside,” and...

Back to the Beach and Thankful for the #ASH21 Experience

Back to the Beach and Thankful for the #ASH21 Experience

What an amazing time it has been at ASH!  #ASH21 #IMFASH21   It was great to see the new trials, updates, and options that are available – or at least soon-to-become available. There was something for almost everyone along their myeloma journey –...

#ASH21 Trial Design Acronyms

#ASH21 Trial Design Acronyms

I was going to write something insightful – my biggest takeaways – from the last two days of the 63rd annual meeting of the American Society of Hematology (ASH) meeting. I started saying that:  the MASTER trial was very patient-centric; it had over 23% African...